Posted by Michael Wonder on 29 Apr 2021
Bavencio receives reimbursement recommendation from pCODR and INESSS for the maintenance treatment of patients with advanced bladder cancer
29 April 2021 - EMD Serono Canada and Pfizer Canada are pleased to announce that Bavencio (avelumab for injection) has received recommendations to be reimbursed with clinical criteria and conditions, from the pan-Canadian Oncology Drug Review and by the Institut national d'excellence en santé et en services sociaux (INESSS).
Bavencio is approved by Health Canada for the maintenance treatment of patients with unresectable locally advanced or metastatic urothelial carcinoma, an advanced type of bladder cancer, whose disease has not progressed following first-line platinum-based chemotherapy.
